

Michael A Weber

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6465083/michael-a-weber-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202
papers

15,539
citations

54
h-index

123
g-index

250
ext. papers

18,107
ext. citations

6.9
avg, IF

6.06
L-index

#	Paper	IF	Citations
202	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet, The</i> , 2004 , 363, 2022-31	40	2112
201	Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. <i>New England Journal of Medicine</i> , 2008 , 359, 2417-28	59.2	1518
200	Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. <i>Circulation</i> , 1997 , 96, 308-15	16.7	1410
199	Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 14-26	2.3	588
198	Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2073-82	27.4	517
197	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. <i>Lancet, The</i> , 2004 , 363, 2049-51	40	472
196	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017 , 390, 2160-2170	40	406
195	Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Hypertension</i> , 2014 , 32, 3-15	1.9	396
194	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018 , 391, 2346-2355	40	358
193	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society	15.1	325
192	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a journal multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2335-2345	40	301
191	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i> , 2011 , 123, 2434-506	16.7	255
190	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. <i>Journal of Hypertension</i> , 2009 , 27, 1360-9	1.9	242
189	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 374, 1423-31	40	222
188	Cardiovascular events during differing hypertension therapies in patients with diabetes. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 77-85	15.1	172
187	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017 , 389, 2226-2237	40	171
186	Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. <i>Hypertension</i> , 2011 , 57, 413-20	8.5	167

185	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2020 , 395, 1444-1451	40	166
184	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. <i>The Lancet Global Health</i> , 2018 , 6, e736-e743	13.6	166
183	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. <i>European Heart Journal</i> , 2019 , 40, 2006-2017	9.5	145
182	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 211-220	18.1	143
181	Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. <i>Hypertension</i> , 2010 , 56, 824-30	8.5	141
180	Combination therapy in hypertension. <i>Journal of the American Society of Hypertension</i> , 2010 , 4, 90-8		134
179	Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONGOing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). <i>Journal of the American College of Cardiology</i> , 2012 , 59, 74-83	15.1	126
178	Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. <i>American Journal of Hypertension</i> , 2004 , 17, 252-9	2.3	119
177	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. <i>Hypertension</i> , 2006 , 48, 385-91	8.5	114
176	The circadian blood pressure pattern in ambulatory normal subjects. <i>American Journal of Cardiology</i> , 1984 , 54, 115-9	3	113
175	The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 81-8	2.3	111
174	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. <i>Journal of Hypertension</i> , 2006 , 24, 2163-8	1.9	110
173	Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. <i>European Heart Journal</i> , 2018 , 39, 2243-2251	9.5	109
172	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 537-45	40	109
171	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016 , 171, 82-91	4.9	104
170	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 259-352		100
169	Exceptional early blood pressure control rates: the ACCOMPLISH trial. <i>Blood Pressure</i> , 2007 , 16, 80-6	1.7	97
168	Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 169-74	15.1	94

167	Lead-induced hypertension: possible role of endothelial factors. <i>American Journal of Hypertension</i> , 1993 , 6, 723-9	2.3	94
166	The role of the new beta-blockers in treating cardiovascular disease. <i>American Journal of Hypertension</i> , 2005 , 18, 169S-176S	2.3	86
165	Changes in ventricular septal thickness during diuretic therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 283-8	6.1	86
164	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2017 , 38, 93-100	9.5	79
163	Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. <i>Contemporary Clinical Trials</i> , 1998 , 19, 370-90		75
162	Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. <i>American Journal of Hypertension</i> , 1992 , 5, 247S-251S	2.3	74
161	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. <i>American Journal of Hypertension</i> , 2004 , 17, 793-801	2.3	69
160	Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. <i>Blood Pressure</i> , 2016 , 25, 93-103	1.7	68
159	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. <i>European Heart Journal</i> , 2016 , 37, 955-64	9.5	68
158	Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 760-9	2.3	68
157	Cardiac muscle mass during vasodilation therapy of hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 727-32	6.1	67
156	β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 872-81	5.8	62
155	Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. <i>American Journal of Medicine</i> , 2012 , 125, 1229.e1-1229.e10	2.4	59
154	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007 , 16, 13-9	1.7	59
153	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019 ,	16.7	58
152	Characterization of Antihypertensive Therapy by Whole-Day Blood Pressure Monitoring. <i>JAMA - Journal of the American Medical Association</i> , 1988 , 259, 3281	27.4	57
151	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. <i>American Heart Journal</i> , 2006 , 151, 176-84	4.9	55
150	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>European Heart Journal</i> , 2018 , 39, 3105-3114	9.5	54

149	Arterial compliance abnormalities in isolated systolic hypertension. <i>American Journal of Hypertension</i> , 2001 , 14, 1007-11	2.3	54
148	The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. <i>European Heart Journal</i> , 2017 , 38, 712-719	9.5	52
147	Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. <i>Lancet, The</i> , 2014 , 383, 1889-98	4.0	52
146	Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. <i>Hypertension</i> , 2012 , 60, 310-8	8.5	51
145	Disparate patterns of aldosterone response during diuretic treatment of hypertension. <i>Annals of Internal Medicine</i> , 1977 , 87, 558-63	8	51
144	Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. <i>American Journal of Hypertension</i> , 2004 , 17, 37-42	2.3	49
143	Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. <i>Hypertension</i> , 2011 , 57, 174-9	8.5	48
142	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2476-2486	4.0	47
141	The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?. <i>American Journal of Cardiology</i> , 2002 , 89, 27A-33A	3	46
140	Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application. <i>Journal of Hypertension</i> , 2019 , 37, 905-916	1.9	45
139	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019 , 40, 743-751	9.5	44
138	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. <i>Blood Pressure</i> , 2016 , 25, 83-92	1.7	41
137	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. <i>Blood Pressure</i> , 2008 , 17, 7-17	1.7	41
136	The ALLHAT report: a case of information and misinformation. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 9-13	2.3	41
135	Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. <i>American Journal of Medicine</i> , 2013 , 126, 501-8	2.4	40
134	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. <i>American Heart Journal</i> , 2018 , 195, 115-129	4.9	39
133	Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 284-92	2.3	37
132	Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 168-74	2.3	37

131	Heredity and hypertension: impact on metabolic characteristics. <i>American Heart Journal</i> , 1992 , 124, 435-440	4.0	37
130	Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence. <i>Hypertension</i> , 2019 , HYPERTENSIONAHA11912630	8.5	36
129	Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1095-1105	5	36
128	The abrupt discontinuation of antihypertensive treatment. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 476-86	2.9	34
127	The telmisartan programme of research to show Telmisartan End-organ protection (PROTECTION) programme. <i>Journal of Hypertension</i> , 2003 , 21, S37-46	1.9	32
126	The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol. <i>American Journal of Medicine</i> , 1978 , 64, 187-92	2.4	32
125	Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 840-9	2.3	29
124	Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 40, 679-85	6.1	29
123	Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7, 45-54	3.9	29
122	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , 2018 , 138, 1602-1604	16.7	28
121	Controlled-release carvedilol in the treatment of essential hypertension. <i>American Journal of Cardiology</i> , 2006 , 98, 32L-38L	3	27
120	The effect of antihypertensive drugs on vascular compliance. <i>Current Hypertension Reports</i> , 2001 , 3, 297-304	4.9	27
119	Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 22-32	8.5	27
118	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012 , 81, 568-76	9.9	26
117	Clinical implications of aldosterone blockade. <i>American Heart Journal</i> , 2002 , 144, S12-8	4.9	26
116	São Paulo call to action for the prevention and control of high blood pressure: 2020. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1744-1752	2.3	25
115	High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 714-7	2.3	24
114	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019 , 40, 2032-2043	9.5	23

113	The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 461-470	5.4	23
112	One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. <i>Hypertension</i> , 2001 , 38, 1118-23	8.5	23
111	Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. <i>Journal of Hypertension</i> , 2012 , 30, 2213-22	1.9	21
110	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2909-2919	15.1	21
109	Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 678-86	2.3	20
108	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 299-307	2.3	20
107	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2922-2933	5	19
106	Creating a combination antihypertensive regimen: what does the research show?. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 12-20	2.3	19
105	Blood pressure effects of combined β -blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 588-92	2.3	18
104	Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. <i>American Journal of Cardiology</i> , 2013 , 112, 255-9	3	18
103	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. <i>Hypertension</i> , 2020 , 76, 1410-1417	8.5	18
102	Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. <i>American Journal of Hypertension</i> , 2003 , 16, 460-6	2.3	17
101	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020 , 41, 231-238	9.5	16
100	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020 , 109, 289-302	6.1	15
99	Calcium channel antagonists in the treatment of hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2002 , 2, 415-31	4	15
98	Low-dose diuretic and beta adrenoceptor blocker in essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 149-58	6.1	15
97	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 1742-1767	1.9	15
96	Hypertension: Cardiovascular benefits of lowering blood pressure. <i>Nature Reviews Nephrology</i> , 2016 , 12, 202-4	14.9	14

95	Blood pressure measurement in special populations and circumstances. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1122-1127	2.3	14
94	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017 , 42, 198-225	17.1	13
93	2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1082-1085	2.3	13
92	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 845-54		13
91	The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the treatment of high blood pressure: similarities and differences. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 103-12	2.9	13
90	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019 , HYPERTENSIONAHA11913081	8.5	12
89	A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 572-8	6.1	12
88	Cardiovascular Safety of the β -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1084-1091	2.9	11
87	Is It Time to Reappraise Blood Pressure Thresholds and Targets? A Statement From the International Society of Hypertension-A Global Perspective. <i>Hypertension</i> , 2016 , 68, 266-8	8.5	11
86	New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>American Journal of Cardiology</i> , 2007 , 100, 45J-52J	3	11
85	Hypertension treatment and implications of recent cardiovascular outcome trials. <i>Journal of Hypertension</i> , 2006 , 24, S37-44	1.9	11
84	Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 322-9	2.3	11
83	Blood pressure monitoring for assessing the duration of action of antihypertensive treatment. <i>Journal of Clinical Pharmacology</i> , 1987 , 27, 751-5	2.9	11
82	Differential effects of diuresis and beta-adrenoreceptor blockade during angiotensin-converting enzyme inhibition in patients with severe hypertension. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 179-86 ⁹	2.9	11
81	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. <i>Lancet, The</i> , 2022 , 399, 1401-1410	4.0	11
80	Global Implications of Blood Pressure Thresholds and Targets: Guideline Conversations From the World Hypertension League. <i>Hypertension</i> , 2018 , 71, 985-987	8.5	10
79	Treatment of patients with hypertension and arthritis pain: new concepts. <i>American Journal of Medicine</i> , 2009 , 122, S16-22	2.4	10
78	Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 346-52	6.1	10

77	Overview of Fosinopril. <i>Drug Investigation</i> , 1991 , 3, 3-11		10
76	The Accuracy in Measurement of Blood Pressure (AIM-BP) collaborative: Background and rationale. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1780-1783	2.3	10
75	Recently published hypertension guidelines of the JNC 8 panelists, the American Society of Hypertension/International Society of Hypertension and other major organizations: introduction to a focus issue of the Journal of Clinical Hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 241-5	2.3	9
74	The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. <i>Journal of the Cardiometabolic Syndrome</i> , 2008 , 3, 229-33		9
73	Differing roles of body mass and the renin-angiotensin system in mediating the hypertension syndrome. <i>American Journal of Nephrology</i> , 2000 , 20, 169-74	4.6	9
72	Centrally acting antihypertensive agents: a comparison of lofexidine with clonidine. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 65-71	2.9	9
71	Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2014 , 19, 90-7	1.3	8
70	Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?. <i>Journal of Hypertension</i> , 2009 , 27, S9-14	1.9	8
69	Outcomes of treating hypertension in the elderly: a short commentary on current issues. <i>The American Journal of Geriatric Cardiology</i> , 2003 , 12, 14-8		8
68	Vasoconstrictor effects of aldosterone in isolated vascular tissue. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1583-91		8
67	Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5, 148-55	3.9	8
66	Beta-blockers in the treatment of hypertension: new data, new directions. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 234-8	2.3	7
65	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. <i>Blood Pressure</i> , 2008 , 17, 260-9	1.7	7
64	Angiotensin II receptor blockers in older patients. <i>The American Journal of Geriatric Cardiology</i> , 2004 , 13, 197-205; quiz 206-7		7
63	Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 62-73	3	7
62	Sympathetic nervous system and hypertension. Therapeutic perspectives. <i>American Journal of Hypertension</i> , 1989 , 2, 147S-152S	2.3	7
61	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 725-731	6.1	7
60	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 695-701	2.3	6

59	Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. <i>Hypertension</i> , 2020 , 75, 1584-1592	8.5	6
58	Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 356-365	2.3	6
57	Managing the patient at risk for a second stroke. <i>Journal of Hypertension</i> , 2005 , 23, S41-7	1.9	6
56	Clinical pharmacology of centrally acting antihypertensive agents. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 598-602	2.9	6
55	Renin subgroups in essential hypertension. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1817-34		6
54	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study. <i>Hypertension</i> , 2021 , 77, 529-536	8.5	6
53	Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. <i>Managed Care Interface</i> , 2005 , 18, 47-54		6
52	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
51	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021 , 16, e1496-e1502	3.1	5
50	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, 416-426	2.7	5
49	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1028-1038	15.1	5
48	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. <i>Blood Pressure Monitoring</i> , 2018 , 23, 153-163	1.3	4
47	Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial. <i>The American Journal of Geriatric Cardiology</i> , 2004 , 13, 131-6		4
46	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021 , 233, 98-99	4.9	4
45	Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 141-6	2.3	3
44	Predictors of systolic BP . <i>Blood Pressure</i> , 2012 , 21, 82-7	1.7	3
43	Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. <i>Current Hypertension Reports</i> , 2004 , 6, 291-2	4.7	3
42	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	3

41	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010075	6	3
40	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , 2022 , 145, 847-863	16.7	3
39	Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 1309-1318	2.3	2
38	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 947-956	1.9	2
37	Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. <i>Endocrine Practice</i> , 2012 , 18, 1029-37	3.2	2
36	Telmisartan in high-risk cardiovascular patients. <i>American Journal of Cardiology</i> , 2010 , 105, 36A-43A	3	2
35	The Therapeutic Implications of Left Ventricular Hypertrophy in the Hypertensive Patient. <i>American Journal of Therapeutics</i> , 1995 , 2, 972-977	1	2
34	Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 1473-1476	1.2	2
33	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. <i>Blood Pressure</i> , 2021 , 30, 90-97	1.7	2
32	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021 , 39, 766-774	1.9	2
31	Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. <i>Reviews in Cardiovascular Medicine</i> , 2007 , 8 Suppl 2, S1-6	3.9	2
30	Optimum antihypertensive therapy: does adiposity matter?. <i>Lancet, The</i> , 2015 , 385, 834-6	40	1
29	A Tribute to Dr John H. Laragh. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 495-8	2.3	1
28	The Physician Payments Sunshine Act: A Setback for Medical Progress. <i>Drug Information Journal</i> , 2012 , 46, 292-293		1
27	An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 241-50; quiz 251-2	2.3	1
26	Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?. <i>Blood Pressure Monitoring</i> , 2003 , 8, 215-22	1.3	1
25	Abstract 109: Changes in Plasma Renin Activity After Renal Denervation in the Spyral Htn-Off Med Trial. <i>Hypertension</i> , 2019 , 74,	8.5	1
24	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. <i>Blood Pressure</i> , 2021 , 30, 82-89	1.7	1

23	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021 , 23, 100818	1.8	1
22	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.. <i>Hypertension</i> , 2022 , 101161	8.5	1
21	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 12	8.7	0
20	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine Infusion Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2021 , 24, 77-86	1.6	0
19	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021 , 39, 1602-1610	1.9	0
18	A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018 , 19, 1470320318795000	2.0	0
17	Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. <i>American Journal of Nephrology</i> , 2021 , 52, 429-434	4.6	0
16	Intensive treatment of hypertension to a SBP . <i>Evidence-Based Medicine</i> , 2017 , 22, 30		
15	MY APPROACH to the patient with hard-to-control hypertension. <i>Trends in Cardiovascular Medicine</i> , 2015 , 25, 755-6	6.9	
14	Obesity, blood pressure, and cardiovascular outcomes - Authors Reply. <i>Lancet, The</i> , 2013 , 381, 1982-3	4.0	
13	Remembering Dr Marvin Moser. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 1-4	2.3	
12	John Laragh and the renin thesis: creating a paradigm. <i>American Journal of Hypertension</i> , 2014 , 27, 1008-9	2.3	
11	Secondary analysis of the VALUE trial: intriguing new questions. <i>Current Hypertension Reports</i> , 2007 , 9, 261-3	4.7	
10	A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. <i>Current Hypertension Reports</i> , 2003 , 5, 319-21	4.7	
9	The JNC 7 report: challenges and dilemmas in writing guidelines. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 282-6	2.3	
8	Clinical trials report. Vascular effects beyond blood pressure: the CAMELOT study. <i>Current Hypertension Reports</i> , 2005 , 7, 235-7	4.7	
7	The role of aldosterone in the response to treatment of primary hypertension. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1923-34		
6	Mineralocorticoids in Essential and Secondary Hypertension Introduction to the Symposium. <i>Clinical and Experimental Hypertension</i> , 1982 , 4, 1447-1450		

- 5 Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. *American Journal of Hypertension*, **2021**, 34, 531-539 2.3
- 4 The Metabolic Syndrome **2007**, 678-690
- 3 Progression of Chronic Kidney Disease in Patients with Diabetes: Implications for Practice. *Endocrine Practice*, **2013**, 19, 8-13 3.2
- 2 Treating hypertension: who speaks for the patient?. *Journal of Human Hypertension*, **2021**, 35, 1057-1058.6
- 1 The World Hypertension League becomes a partner of the Journal of Human Hypertension. *Journal of Human Hypertension*, **2021**, 35, 821-822 2.6